Press Release

Global Non-alcoholic Steatohepatitis (NASH) Treatment Market 2020 Global Analysis, Segments, Size, Share, Industry Growth and Recent Trends by Forecast to 2026

The global non-alcoholic steatohepatitis (NASH) treatment market size is projected to gain impetus from a rise in the incidence of diabetes. This information is provided in an upcoming report by Fortune Business Insights, titled, “Non-alcoholic Steatohepatitis Treatment Market Size, Share and Global Trend By Drug Class (PPAR agonists, FXR-bile acid axis, Anti-oxidants, GLP-1/DPP-4/SGLT-2 agent, Anti-inflammatory agents, Anti-fibrotic), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography Forecast till 2026.”

Segmentation of the Non-alcoholic Steatohepatitis (NASH) Treatment Market

By Drug Class            

  • PPAR agonists
  • FXR-bile acid axis
  • Anti-oxidants
  • GLP-1/DPP-4/SGLT-2 agent
  • Anti-inflammatory agents
  • Anti-fibrotic
  • Others

By Distribution Channel      

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography           

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)

Ability to Reduce Weight to Fuel Glucagon-like Peptide-1 Receptor Drugs Segment

On the bases of drug class, the global NASH treatment market is divided into PPAR agonists, FXR-bile acid axis, anti-oxidants, GLP-1/DPP-4/SGLT-2 agent, anti-inflammatory agents, anti-fibrotic, and others. Out of these, the Glucagon-like peptide-1 receptor (GLP-1R) drugs are projected to acquire the largest global non-alcoholic steatohepatitis treatment market share during the forthcoming years. It would occur because these agonists drugs aid in decreasing weight, which further reduces fast accumulation in the liver and prevents a person from NASH.


More Trending Topics From Fortune Business [email protected]

Sternal Closure Systems Market

Injectable Reproductive Hormone Market

Serum Free Light Chain (sFLC) Assays Market

Brain Stroke Market

Pseudobulbar Affect Treatment Market

Obstructive Sleep Apnea Diagnostics Market

Newborn Screening Market

Stone Retrieval Basket Market

Dale Martinez

Dale possesses an engineering degree in Electronics from the Georgia Institute of Technology. She is the sole contributor at the Healthcare IT column. Before opting to write, Dale worked at major firms such as Microsoft, Amazon, GE, Raytheon, and so on. She possesses vast knowledge about a variety of fields like IT, IoT, Telecommunications, Health Dialysis, photovoltaic, and many others. Dale is also a ballet dancer.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *